Synbio Tech (1295) Fundamentals 2026 — P/E 11.0x, Revenue Analysis | SniperIQ
Synbio Tech (1295) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Synbio Tech's market cap?
Synbio Tech (1295) has a market capitalization of approximately NT
What is Synbio Tech's P/E ratio?
Synbio Tech's trailing twelve-month P/E ratio is 11.0x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Synbio Tech?
Synbio Tech runs a net profit margin of 14.7%, a gross margin of 51.3%, and an operating margin of 16.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Synbio Tech generate?
Synbio Tech reported revenue of NT
Does Synbio Tech pay a dividend?
Synbio Tech offers a trailing dividend yield of about 6.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Synbio Tech financially healthy?
Synbio Tech carries a debt-to-equity ratio of 1.33x and a current ratio of 1.04x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Synbio Tech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Synbio Tech (1295) the key facts are: market cap NT
Track Synbio Tech's full fundamentals live
Get Synbio Tech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.